Inversago Pharma Inc.

Skye Bioscience has abandoned its plans in ophthalmology after a Phase II failure and will now focus exclusively on its obesity candidate, the cannabinoid 1 receptor (CB1) inhibitor nimacimab. The im

For any other company, spending €235m ($256m) on a preclinical program with an unproven mechanism might be a punchy move. But Novo Nordisk A/S has money to burn thanks to its wildly successful diabe

The growing competition between Novo Nordisk and Eli Lilly in diabetes and obesity has been one of the biggest stories of 2023, and venture capital firm Forbion has been a major beneficiary, selli

A heady start for biopharmaceutical M&A during the first half of 2023 slowed to a crawl during Q3 and particularly the months of August and September, as data recorded by Evaluate show. Biogen, Inc.